This review takes a look at something most of us rarely consider: when we eat, not just what we eat. The authors outline how habitual late-night eating disrupts the body’s circadian rhythm, desynchronizing the central clock in the brain from other clocks in organs like the liver and gut. That misalignment appears to weaken DNA repair, alter clock-gene expression and promote inflammatory and cancer forming signaling.

At the same time, eating during the biological night reshapes the gut microbiome in unfavorable ways. While much of the strongest evidence comes from preclinical studies, the consistency of these pathways helps explain the concerning rise in early-onset digestive cancers seen over the past two decades.

This paper highlights meal timing as a modifiable behavior that may influence early carcinogenic processes long before cancer develops. The authors point to daytime-aligned eating as a potential countermeasure, not because it reduces calories, but because it restores circadian alignment and microbial rhythm.

The takeaway for readers is: chronic late-night eating may be one of the many modern habits pushing metabolism, inflammation and cancer risk in the wrong direction. Aligning food intake with our internal clocks may be a low-cost, low-risk way to stack the odds more favorably over time.

This comprehensive review pulls together a growing body of evidence showing that the gut microbiome functions like a regulator of cardiovascular health. The authors describe a “gut–heart axis” in which microbial metabolites influence vascular inflammation, lipid handling, blood pressure regulation and even arrhythmia risk.

Dietary patterns consistently shape microbial behavior: Mediterranean-style diets rich in fiber and polyphenols promote protective metabolites, while Western diets high in saturated fat and processed foods push the system toward inflammation and vascular dysfunction. Exercise appears to reinforce these benefits by improving microbial diversity and gut barrier integrity.

The practical message for readers is straightforward: cardiovascular risk is influenced not only by cholesterol numbers and blood pressure readings, but also by daily choices that shape the gut environment.

This paper explores a question that has been circulating for years but rarely examined at the molecular level: why obstructive sleep apnea (OSA) appears to be associated with a higher risk of PCa (yes, it’s a thing). The authors take a genetic approach, comparing known risk genes for OSA with those linked to PCa. They identify 68 overlapping genes (far more than would be expected by chance) clustered around pathways for carcinogenesis, including hypoxia signaling, oxidative stress, inflammation and cell-cycle regulation. Intermittent hypoxia, a defining feature of sleep apnea, emerges as a plausible biological bridge, activating inflammatory pathways, all of which are deeply involved in tumor growth.

Understand that this is not proof that sleep apnea causes PCa, nor does it suggest that every man with OSA is destined for aggressive disease. What it does show is that both conditions appear to converge on the same molecular stress responses that are known to accelerate cancer progression.

If future studies confirm that effective treatment, such as CPAP therapy, reduces inflammatory or hypoxia-driven cancer signaling, sleep quality may become a meaningful part of long-term cancer risk management.

This review tackles one of the longest-standing problems in PCa screening: PSA finds a lot, but it does not discriminate well. Even in the MRI era, too many men still undergo biopsies that ultimately show no clinically significant cancer. The authors focus on a newer biomarker, S2,3PSA%, which doesn’t measure how much PSA is present, but rather what kind of PSA is circulating. Across multiple test groups, higher S2,3PSA% values track closely with higher Gleason scores and clinically significant PCa, while remaining largely independent of PSA concentration itself.

This is not a replacement for PSA or MRI, but it represents a shift toward biologically informed decision-making, moving beyond “how high is the PSA?” to “what is the prostate actually doing?” If validated broadly, this approach could help spare many men invasive procedures while keeping attention focused where it truly belongs.

I chose to include this paper because I saw my oncologist’s name in the list of authors. This consensus paper summarizes the conclusions of a multidisciplinary expert panel convened to identify gaps across the entire PCa continuum. The authors emphasize that while treatment options have expanded rapidly, precision has not kept pace.

PSMA-PET imaging is now central to staging and recurrence assessment, but its sensitivity introduces new challenges, including false positives and uncertainty about how aggressively to treat PET-only disease.

The panel devotes substantial focus to complications of therapy such as bone loss, cardiovascular risk, cognitive decline, depression and sleep disturbances, arguing that these are not side issues but core outcomes that meaningfully affect survival and quality of life.

In addition, they call for routine cardiovascular risk assessment in men on androgen deprivation therapy, better integration of primary care and cardio-oncology and earlier attention to lifestyle interventions such as physical activity, plant-forward nutrition and sleep health.

The future of PCa care is not simply more drugs, but smarter sequencing, better biomarkers and a broader definition of success that includes how men live during and after treatment.